Harmony Biosciences Holdings (HRMY) Operating Margin (2020 - 2026)

Harmony Biosciences Holdings has disclosed Operating Margin across 7 years of filings, most recently posting 3.87% for Q1 2026.

• Operating Margin for Q1 2026 came in at 3.87%, down 2658.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.31% (down 2649.0% YoY), and the FY2025 annual result was 5.2%, down 2150.0% from the prior year.
• Operating Margin came in at 3.87% for Q1 2026 at Harmony Biosciences Holdings, up from 51.17% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 40.25% in Q3 2023 to a low of 51.17% in Q4 2025.
• The 5-year median for Operating Margin is 30.45% (2025), against an average of 22.64%.
• Across the five-year window, Operating Margin soared 3010 bps in 2023 and sank 7886 bps in 2025, its largest moves.
• Harmony Biosciences Holdings' Operating Margin stood at 37.11% in 2022, then sank by 36 bps to 23.87% in 2023, then advanced by 16 bps to 27.69% in 2024, then slumped by 285 bps to 51.17% in 2025, then soared by 108 bps to 3.87% in 2026.
• The last three Operating Margin figures came in at 3.87% (Q1 2026), 51.17% (Q4 2025), and 27.35% (Q3 2025), per Business Quant data.